Department of Neurology and Neuroscience, Weill Cornell Medical College/New York Presbyterian Hospital, NY 10065-4885, USA.
J Neurol Sci. 2013 Mar 15;326(1-2):1-9. doi: 10.1016/j.jns.2013.01.003. Epub 2013 Jan 19.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a group of idiopathic, acquired, immune-mediated inflammatory demyelinating diseases of the peripheral nervous system. A majority of patients with CIDP respond to "first-line" treatment with IVIG, plasmapheresis and/or corticosteroids. There exists insufficient evidence to ascertain the benefit of treatment with "conventional" immunosuppressive drugs. The inconsistent efficacy, long-term financial burden and health risks of non-specific immune altering therapy have drawn recurrent attention to the possible usefulness of a variety of biological agents that target key aspects in the CIDP immunopathogenic pathways. This review aims to give an updated account of the scientific rationale and potential use of biological therapeutics in patients with CIDP. No specific treatment recommendations are given. The discovery, development and application of biological markers by modern molecular diagnostic techniques may help identify drug-naïve or treatment-resistant CIDP patients most likely to respond to targeted immunotherapy.
慢性炎症性脱髓鞘性多发性神经病（CIDP）是一组特发性、获得性、免疫介导的周围神经系统脱髓鞘疾病。大多数 CIDP 患者对 IVIG、血浆置换和/或皮质类固醇的“一线”治疗有反应。目前尚无足够证据确定“常规”免疫抑制药物治疗的益处。非特异性免疫改变治疗的疗效不一致、长期经济负担和健康风险反复引起人们对靶向 CIDP 免疫发病途径关键方面的各种生物制剂的可能有效性的关注。本综述旨在提供 CIDP 患者使用生物治疗的科学依据和潜在用途的最新说明。未给出具体的治疗建议。现代分子诊断技术所发现、开发和应用的生物标志物可能有助于识别最有可能对靶向免疫治疗有反应的药物初治或治疗抵抗性 CIDP 患者。
